Mesenchymal Precursor Cells Reduce Mortality and Major Morbidity in Ischaemic Heart Failure with Inflammation: DREAM-HF
Ischaemic aetiology and inflammation were identified as major risk factors for MACE in control DREAM-HF patients. A single intramyocardial MPC administration produced the most significant, sustained reduction in 2-point and 3-point MACE in patients with ischaemic HFrEF and inflammation.
Authors
- Timothy D. Henry (ORCID: https://orcid.org/0000-0003-1123-0533)
- Jack P. Hayes (ORCID: https://orcid.org/0000-0001-5464-4387)
- Kenneth M. Borow
- Hicham Skali (ORCID: https://orcid.org/0000-0002-5629-4138)
- Christopher W. James (ORCID: https://orcid.org/0009-0001-0854-8041)
- Eric A. Rose
- Barry Greenberg (ORCID: https://orcid.org/0000-0002-6605-9385)
- Olga Rutman
- Silviu Itescu
- Emerson C. Perin (ORCID: https://orcid.org/0000-0002-3622-9814)
- Margaret Jenkins
Institutions
- Brigham and Women's Hospital (US)
- Center for Global Development (US)
- Harvard University (US)
- University of California San Diego (US)
- Mesoblast (United States) (US)
- Houston Institute for Clinical Research (US)
- Center for Clinical Research (United States) (US)
- Christ Hospital (US)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1002/ejhf.3522
- Citations
- 3
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.21